The present disclosure relates to a system for controlling gas production within drug delivery devices. More particularly, the present disclosure relates to liquid base-polymeric acid chemical reaction systems for controlling gas generation rates for propelling a therapeutic fluid from a drug delivery device.
Recently, chemical reaction systems have been used to power the delivery of therapeutic fluids through drug delivery devices. In general, the chemical reaction systems used have included a liquid acid-powder base reaction that generates a gas that in turn is used to propel and deliver the therapeutic fluid from the drug delivery device. However, it has proven difficult to control the rate of these reactions, specifically as needed for the slow delivery of the therapeutic fluid.
As such, it would be desirable to provide reaction systems capable of controlling the rate at which a therapeutic fluid is administered from a drug delivery device, specifically controlling the rate such that the therapeutic fluid is capable of being delivered in a slower manner. These reaction systems may be used to deliver any number of therapeutic fluids, for example, high-concentration proteins, high-viscosity pharmaceutical formulations, or other therapeutic fluids.
The present disclosure provides a system for controlling the generation of gas within a drug delivery device. More specifically, the present disclosure provides a liquid base-polymeric acid chemical reaction system that is capable of controlling the rate of gas generation within the drug delivery device to control a speed of delivery of a therapeutic fluid from the drug delivery device.
According to an embodiment of the present disclosure, a device is disclosed for delivering a therapeutic fluid by a chemical reaction. The device includes a housing having a first chamber, a second chamber, and a third chamber. The device has a loaded configuration in which the first chamber contains a liquid base, the second chamber contains a polymeric acid, and the third chamber contains the therapeutic fluid, and a delivery configuration in which the liquid base reacts with the polymeric acid and generates a propellant gas that delivers the therapeutic fluid from the third chamber.
According to another embodiment of the present disclosure, a method is disclosed for delivering a therapeutic fluid by a chemical reaction, the method comprising: providing a device containing a liquid base, a polymeric acid, and a therapeutic fluid, the liquid base configured to react with the polymeric acid to generate a propellant gas that delivers the therapeutic fluid from the device.
The above-mentioned and other features and advantages of this disclosure, and the manner of attaining them, will become more apparent and will be better understood by reference to the following description of embodiments of the invention taken in conjunction with the accompanying drawings, wherein:
Corresponding reference characters indicate corresponding parts throughout the several views. The exemplifications set out herein illustrate exemplary embodiments of the invention and such exemplifications are not to be construed as limiting the scope of the invention in any manner.
The present disclosure provides systems for generating gas used to operate drug delivery devices. These systems include chemical reaction systems comprising liquid base-polymeric acid reactions that can be adjusted to provide controllable gas release, which allows for a range of slower delivery rates of therapeutic fluids from a drug delivery device.
The therapeutic fluid or drug product to be dispensed from the drug delivery devices of the present disclosure may take various forms, such as a solution, dispersion, suspension, emulsion, or another suitable fluid form. The drug delivery devices are operated in a manner generally as described herein by a patient, caregiver or healthcare professional to deliver drug to a person.
The therapeutic fluid may contain a therapeutically useful agent. The therapeutic agent may include insulin, insulin analog such as insulin lispro or insulin glargine, insulin derivative, GLP-1 receptor agonist such as dulaglutide or liraglutide, glucagon, glucagon analog, glucagon derivative, gastric inhibitory polypeptide (GIP), GIP analog, GIP derivative, oxyntomodulin analog, oxyntomodulin derivative, therapeutic antibody and any therapeutic agent that is capable of delivery by the devices of the present disclosure. The therapeutic agent as used in the device may be formulated with one or more excipients.
In certain embodiments, the agent is protein, such as a monoclonal antibody or some other protein which is therapeutically useful. In some embodiments, the protein may have a concentration of from about 75 mg/mL to about 500 mg/mL in the therapeutic fluid. In certain embodiments, the protein may have a concentration of about 150 mg/mL, 200 mg/mL, 250 mg/mL, or more. The therapeutic fluid may further contain a solvent or non-solvent, such as water, perfluoroalkane solvent, safflower oil, or benzyl benzoate.
In some embodiments, the therapeutic fluid may be considered a high-viscosity fluid and may have an absolute viscosity of from about 5 cP to about 1000 cP. In certain embodiments, the high-viscosity fluid has an absolute viscosity of at least about 10 cP, 20 cP, 30 cP, 40 cP, 50 cP, 60 cP, or more.
Exemplary delivery devices 1000, 1000′ are shown in
The illustrative device 1000 is an elongate structure that extends from a first, distal end 1002 (illustratively, a lower end) to a second, proximal end 1004 (illustratively, an upper end). The illustrative device 1000 includes a substantially cylindrical barrel or housing 1006 containing a piston 1010, a spring 1012, and a plunger 1014. At first end 1002, device 1000 includes a patient delivery mechanism (not shown), such as a syringe or a needle, for example. At second end 1004, device 1000 includes an actuator assembly 1020.
Initially, device 1000 may be provided in a loaded configuration in which piston 1010 is held downward in barrel 1006 to compress spring 1012, as shown in
When device 1000 is ready for use, device 1000 may be moved to an unloaded or delivery configuration to deliver the therapeutic fluid to the patient. This step may involve pressing a button 1022 of actuator assembly 1020 downward relative to barrel 1006. In the illustrated device 1000, the downward movement of button 1022 causes piston 1010 to rotate and frees piston 1010 for upward movement as spring 1012 expands from its compressed state (
The upward movement of piston 1010 causes actuation chamber 1030 to communicate with reaction chamber 1032. The first reagent from actuation chamber 1030 is exposed to the second reagent in reaction chamber 1032, and this exposure leads to a gas-generating chemical reaction inside device 1000. The generated gas causes the pressure in device 1000 to increase, which pushes plunger 1014 downward and forces the therapeutic fluid out of therapeutic fluid chamber 1034 and into the patient.
Additional details regarding device 1000, device 1000′, other suitable devices, and suitable reagents, chemical formulations, and reactions used to operate such devices are further described in the following references, the disclosures of which are expressly incorporated herein by reference in their entirety: U.S. Pat. No. 9,321,581, filed Oct. 15, 2013, and titled “Process and Device for Delivery of Fluid by Chemical Reaction”; U.S. patent application Ser. No. 14/434,586 (U.S. Publication No. 2015/0314070), filed Oct. 15, 2013, and titled “Chemical Engines and Methods for Their Use, Especially in the Injection of Highly Viscous Fluids”; and International (PCT) Application No. PCT/US2018/017547, filed Feb. 9, 2018, and titled “Processes and Devices for Delivery of Fluid by Chemical Reaction”.
There are many suitable chemical reagents that can be used within the drug delivery devices of the present disclosure to generate a gas. Examples of generated gases include carbon dioxide gas, nitrogen gas, oxygen gas, chlorine gas, etc. Desirably, the generated gas is inert and non-flammable. The amount of gas needed to operate the drug delivery device and the desired rate of delivery for the therapeutic fluid may impact the type, amount, phase, and concentration of each reagent used in the device.
According to an exemplary embodiment of the present disclosure, the first reagent is a liquid reagent and the second reagent is a polymer reagent. In one particular embodiment, the liquid reagent is a liquid base and the polymer reagent is a polymeric acid. As shown in Example 1 below, such liquid base-polymeric acid reactions may proceed at a slower and more linear rate than traditional non-polymer based reactions, for example. This liquid base-polymeric acid combination uses the diffusion properties of the polymer to control the rate of the reaction and thus the production of gas and delivery rate of the therapeutic fluid.
Returning to the illustrated device 1000 of
Examples of suitable liquid bases include sodium bicarbonate, potassium bicarbonate, and potassium carbonate. Other ingredients may also be present along with the bicarbonates, such as diatomaceous earth solid particles. In various embodiments, the liquid base may be a solid dissolved in a solvent or solvent and non-solvent (e.g., water) mixture, while in other embodiments, the liquid base is in a liquid phase. In addition, the liquid base may be insoluble in alcohols (i.e., potassium bicarbonate). The liquid base may also comprise a solid base and a liquid solvent that are initially separate in a loaded configuration of the device and combined in response to an actuation of the device.
In various embodiments, the polymeric acid may be formed as a powder, a dry absorbent polymer matrix formed in various ways, or a gel. For example, the polymeric acid of the present disclosure may be prepared by performing a gel polymerization process. This process may involve mixing one or more liquid acids (which may also be referred to herein as “primary” liquid acids), a desired amount of water, one or more photoinitiators, and one or more cross-linkers, if applicable. Examples of suitable liquid acids include acrylic acid, methacrylic acid, malleic acid, and combinations thereof. The acid solution can then be formed into various shapes and cured with UV light for a period of time. The UV light drives the polymerization and cross-linking reactions to form polyacrylic acid (PAA) gel, polymethacrylic acid (PMAA) gel, polymalleic acid gel, or combinations thereof. For example, 14 millimeter gel discs may be prepared with an acid solution made of liquid acid, 0.5% of a photoinitiator (e.g., methylpropiophenon), and 5000 parts per million of a cross-linker (e.g., acrylamide, ethylene glycol) that is drawn into a syringe with a 30-gauge needle and injected between two glass plates through rubber o-rings to form discs, which are then UV cured for one minute. A dry absorbent polymer matrix may be formed in numerous ways, including, for example, compression molding, injection molding, electrospinning, and film casting.
In forming the polymeric acid, the water content of the acid solution, curing conditions, pH of the acid solution, and other variables may be adjusted to change properties of the polymeric acid. In one particular embodiment of a chemical reaction system of the present disclosure, PAA gel is the polymeric acid and potassium bicarbonate is the liquid base. These reagents may react to produce carbon dioxide gas. In operation, when the liquid base comes into contact with the polymeric acid gel, the base diffuses into the free volume of the polymeric acid gel, reacts with new acidic moieties, and generates gas. The reaction is complete when the liquid base has fully diffused, reacted, and equilibrated within the polymeric acid gel. The free volume (e.g., cavities, etc.) within the polymeric acid in gel form may be modified to alter the diffusion of the base into the gel and therefore the reaction between the reactants and gas production.
In general, the polymeric acid may be the limiting reactant in the chemical reaction systems of the present disclosure. In an exemplary embodiment, if an excess amount of the polymeric acid is present in the system, such an excess amount may be 7 mol. % or more. This excess amount will increase the available surface area for the chemical reaction and decrease dead volume in the system, which would increase the rate and quantity of gas generated by the system.
As shown in the Examples below, the rate and quantity of gas generated by the liquid base-polymeric acid reaction within the chemical reaction system may be adjusted in a plurality of ways. As a general rule of thumb, the higher the surface area-to-volume ratio, the acid concentration, and/or the cross-linking of the polymeric acid, and the faster the reaction and the production of gas that is used to propel the chemical reaction system, and therefore the faster the delivery of the therapeutic fluid.
The surface area-to-volume ratio of the chemical reaction system can be controlled in a variety of ways to adjust the rate and quantity of gas generated. For example, changing the shape and/or form of the polymeric acid to increase its surface area (i.e., making thin sheets of the polymeric acid in gel form, pelletizing the polymeric acid, or electrospinning the polymeric acid into fibers) may increase the reaction rate and delivery rate. In the fiber embodiment, the presence of the fibers themselves may also improve wettability of the acid or the tendency of one fluid to spread on, or adhere to, a surface of the acid through capillary wetting. The size and arrangement of the fibers themselves may be controlled during the electrospinning process, such as by using a relatively large target electrode to produce straight and loosely-packed fibers or a relatively small target electrode to produce curled and densely-packed fibers.
Additionally, the concentration/water content of the acid in the chemical reaction system is controllable to adjust the rate and quantity of gas generated. For example, higher quantities of the primary acid used to form the polymeric acid may be added, other secondary acids, for example citric acid, may be present along with the polymeric acid, and/or the water content of the primary acid may be reduced to increase the acid concentration and therefore increase the reaction rate of the reagents within the chemical reaction system. In some embodiments, the secondary acids or other ingredients do not necessarily chemically bond to the polymeric acid or the base reagents, but rather may either be applied to the surface of the polymeric acid matrix or gel or mixed within the polymeric acid form. In embodiments where the secondary acid sits on the surface of the polymeric acid, the liquid base may quickly reach and react with the secondary acid for an initial pressure boost. By contrast, in embodiments where the secondary acid is embedded in the cavities of the polymeric acid, the reaction between the liquid base and the secondary acid may be delayed and prolonged for an extended pressure boost. In general, the higher the acid concentration or the lower the water content, the faster the reaction of the chemical reaction system, and thus the faster the delivery rate of the therapeutic fluid from the drug delivery device (see
Furthermore, in various embodiments, the polymeric acid reagent may be cross linked to adjust the rate and quantity of gas generated within the chemical reaction system. Cross-linking reduces the solubility of the polymeric acid (e.g., fibers) in the aqueous reaction mixture allowing the polymeric acid to retain it form, swell like a sponge and increase the surface area of contact rather than dissolving and collapsing. The physical swelling of the polymeric acid may also contribute to the pressure increase in the drug delivery device. Thus, cross-linking the polymeric acid produces a faster reaction rate of the reagents, and thus a faster the delivery rate of the therapeutic fluid. In addition, by heating the fibers during cross-linking, moisture is dried off the fibers of the polymeric acid allowing the dry fibers to take up the aqueous reaction mixture more quickly and completely, thus increasing the delivery rate even more.
In this Example, the inventors evaluated the generated pressure and reaction rate in a drug delivery device (expressed as pressure (psig) vs. time (s)) and the resulting therapeutic delivery or flow rate of a therapeutic fluid (expressed as mass (g) vs. time (s)) having a viscosity of about 20 cP at a temperature of about 20° C.
With reference to
Two separate variations of the gel discs of the polymeric acid were prepared. One variation included 100% acrylic acid, while the other variation included 80% acrylic acid. The gel discs, having 14 millimeter diameters, were prepared by mixing liquid acrylic acid, 0.5 wt. % of methylpropiophenone, and 5000 parts per million of acrylamide, drawing the solution into a syringe with a 30-gauge needle, injecting the solution between two glass plates through rubber o-rings, and then curing the formed discs with UV light for approximately one minute. Additionally, a liquid solution of dissolved potassium bicarbonate was prepared to a concentration of 25 mg/mL. Three 150 mg acrylic acid gel discs totaling 450 mg were placed in a pressure vessel, which was subsequently closed and connected to a pressure sensor. Then, 2.5 mL of the potassium bicarbonate solution was injected into the pressure vessel and data was read from the pressure sensor. As shown in
In this Example, the inventors evaluated the generated pressure rate in a drug delivery device (expressed as pressure (psig) vs. time (s)) and the resulting therapeutic delivery rate of a therapeutic fluid (expressed as mass (g) vs. time (s)) having a viscosity of about 20 cP at a temperature of about 20° C. (density of 1.17 g/mL).
In total, the reaction rate, the pressure generation rate, and the resulting therapeutic delivery rate of the chemical reaction system of the present disclosure can be controlled across a wide range. As such, the delivery rate of the therapeutic fluid from the drug delivery device can also be controlled across a wide range. With reference to
While this invention has been described as having exemplary designs, the present invention can be further modified within the spirit and scope of this disclosure. This application is therefore intended to cover any variations, uses, or adaptations of the invention using its general principles. Further, this application is intended to cover such departures from the present disclosure as come within known or customary practice in the art to which this invention pertains and which fall within the limits of the appended claims.
This application claims priority to U.S. Provisional Application No. 62/555,808, filed Sep. 8, 2017, the disclosure of which is hereby expressly incorporated by reference herein in its entirety.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2018/049048 | 8/31/2018 | WO |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2019/050791 | 3/14/2019 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
2390246 | Folkman | Dec 1945 | A |
2446429 | Nelson et al. | Aug 1948 | A |
2833745 | Filkentscher | May 1958 | A |
2923243 | Crockford et al. | Feb 1960 | A |
3405845 | Cook et al. | Oct 1968 | A |
3467526 | Mitchell et al. | Sep 1969 | A |
3556803 | Ehrreich, III et al. | Jan 1971 | A |
3594410 | Cohen et al. | Jul 1971 | A |
3754993 | Oguchi et al. | Aug 1973 | A |
3773111 | Dunn | Nov 1973 | A |
3968796 | Baker | Jul 1976 | A |
4031889 | Pike | Jun 1977 | A |
4203441 | Theeuwes | May 1980 | A |
4675174 | Eckenhoff | Jun 1987 | A |
4744786 | Hooven | May 1988 | A |
4785972 | LeFevre | Nov 1988 | A |
4795748 | Ross et al. | Jan 1989 | A |
5034114 | Kukin | Jul 1991 | A |
5062834 | Gross et al. | Nov 1991 | A |
5151093 | Theeuwes et al. | Sep 1992 | A |
5167641 | Schmitz | Dec 1992 | A |
5279607 | Schentag | Jan 1994 | A |
5304128 | Haber et al. | Apr 1994 | A |
5312389 | Theeuwes et al. | May 1994 | A |
5398850 | Sancoff et al. | Mar 1995 | A |
5518145 | Chen | May 1996 | A |
5540665 | Mercado et al. | Jul 1996 | A |
5645824 | Lim et al. | Jul 1997 | A |
5700245 | Sancoff et al. | Dec 1997 | A |
5855761 | Joshi | Jan 1999 | A |
5858001 | Tsals et al. | Jan 1999 | A |
5871125 | Gross | Feb 1999 | A |
5891087 | Ohtani et al. | Apr 1999 | A |
5941857 | Nguyen et al. | Aug 1999 | A |
5992700 | McGlothlin et al. | Nov 1999 | A |
6086568 | Caizza | Jul 2000 | A |
6086569 | Schweizer | Jul 2000 | A |
6156014 | Petersen et al. | Dec 2000 | A |
6270479 | Bergens et al. | Aug 2001 | B1 |
6431468 | Brown et al. | Aug 2002 | B1 |
6575961 | Joshi | Jun 2003 | B2 |
6786365 | Kim | Sep 2004 | B2 |
6830560 | Gross et al. | Dec 2004 | B1 |
6913593 | Alexandre et al. | Jul 2005 | B1 |
6964356 | Kim | Nov 2005 | B2 |
7632245 | Cowan et al. | Dec 2009 | B1 |
7717877 | Lavi et al. | May 2010 | B2 |
7753884 | Gallnböck | Jul 2010 | B2 |
7985309 | Kim | Jul 2011 | B2 |
7988663 | Schiller et al. | Aug 2011 | B2 |
8157769 | Cabiri | Apr 2012 | B2 |
8353426 | Wold et al. | Jan 2013 | B2 |
8353679 | Yamamoto et al. | Jan 2013 | B2 |
9321581 | Bennison et al. | Apr 2016 | B2 |
20010025168 | Gross et al. | Sep 2001 | A1 |
20010050085 | Knudson et al. | Dec 2001 | A1 |
20020156461 | Joshi | Oct 2002 | A1 |
20030168480 | Kim | Sep 2003 | A1 |
20040249339 | Willis et al. | Dec 2004 | A1 |
20050006401 | Kim | Jan 2005 | A1 |
20050187522 | Miller | Aug 2005 | A1 |
20060235264 | Vassallo | Oct 2006 | A1 |
20070088337 | Lautenbach | Apr 2007 | A1 |
20070228071 | Kamen et al. | Oct 2007 | A1 |
20080066766 | Paraschac et al. | Mar 2008 | A1 |
20080069811 | Zaidi | Mar 2008 | A1 |
20080233029 | Fan et al. | Sep 2008 | A1 |
20080257915 | Wold | Oct 2008 | A1 |
20090093787 | Barbour | Apr 2009 | A1 |
20090131860 | Nielsen | May 2009 | A1 |
20090227942 | Stroem Hansen et al. | Sep 2009 | A1 |
20090259176 | Yairi | Oct 2009 | A1 |
20090259179 | Hillios et al. | Oct 2009 | A1 |
20100030152 | Lee et al. | Feb 2010 | A1 |
20100069846 | Stamp | Mar 2010 | A1 |
20100137808 | Wilmot et al. | Jun 2010 | A1 |
20100174225 | Pesach et al. | Jul 2010 | A1 |
20110054390 | Searle et al. | Mar 2011 | A1 |
20110092906 | Bottger et al. | Apr 2011 | A1 |
20110270188 | Caffey et al. | Nov 2011 | A1 |
20110272271 | Hong et al. | Nov 2011 | A1 |
20120078216 | Smith et al. | Mar 2012 | A1 |
20130253472 | Cabiri | Sep 2013 | A1 |
20140103075 | Bennison et al. | Apr 2014 | A1 |
20150314070 | Heintz | Nov 2015 | A1 |
20160156060 | Hamelers et al. | Jun 2016 | A1 |
20160213846 | Bennison et al. | Jul 2016 | A1 |
20160213847 | Bennison et al. | Jul 2016 | A1 |
20160213859 | Sadowski et al. | Jul 2016 | A1 |
Number | Date | Country |
---|---|---|
3809482 | Oct 1989 | DE |
2221076 | Aug 2010 | EP |
2489387 | Aug 2012 | EP |
2004339496 | Dec 2004 | JP |
92019571 | Nov 1992 | WO |
95001198 | Jan 1995 | WO |
95023641 | Sep 1995 | WO |
97028750 | Aug 1997 | WO |
99012593 | Mar 1999 | WO |
99022790 | May 1999 | WO |
99062576 | Dec 1999 | WO |
01000270 | Jan 2001 | WO |
07071485 | Jun 2007 | WO |
09116045 | Sep 2009 | WO |
09144726 | Dec 2009 | WO |
2012122643 | Sep 2012 | WO |
14059444 | Apr 2014 | WO |
2015160600 | Oct 2015 | WO |
2018152018 | Aug 2018 | WO |
Entry |
---|
International Search Report of the International Searching Authority pertaining to International Application No. PCT/US2018/049048; dated Nov. 27, 2018; 6 pages. |
Written Opinion of the International Searching Authority pertaining to International Application No. PCT/US2018/049048; dated Nov. 27, 2018; 8 pages. |
“Development of an on-Demand, Generic, Drug-Delivery System,” Southern Research Institute, 2000 Ninth Avenue South, Birmingham, AL 35255-5305 Aug. 6, 1985; 30 pages. |
Good, Brian T., et al., “An Effervescent Reaction Micropump for Portable Microfluidic Systems,” Lab Chip, 2006, 6, 659-66; 8 pages. |
Jobando, V. O., & Quarles, C. A. Effect of cross-linking on the free volume properties of natural rubber. physica status solidi c (2007), 4(10), 3759-3762; 4 pages. |
Choudalakis, G., & Gotsis, A. D. Free volume and mass transport in polymer nanocomposites. Current opinion in colloid & interface science (2012), 17(3), 132-140; 9 pages. |
Ahmed, Enas M. Hydrogel: Preparation, characterization, and applications: a review. Journal of advanced research (2015), 6(2), 105-121; 17 pages. |
Number | Date | Country | |
---|---|---|---|
20210038816 A1 | Feb 2021 | US |
Number | Date | Country | |
---|---|---|---|
62555808 | Sep 2017 | US |